In contrast, there were 155 (28.0%) events in the IFN+Ara-C arm, of which 128 occurred during first-line treatment with IFN+Ara-C.
IFN+Ara - C rühmas täheldati aga 155 (28, 0%) progresseerumise juhtu, millest 128 ilmnesid esmavaliku IFN+Ara- C ravi ajal.